Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011)

Diagnostic Microbiology and Infectious Disease

Volumn 75, Issue 4, 2013, Pages 417-422

  Sader, Helio S ^a   Flamm, Robert K ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrobial resistance; Daptomycin; MRSA; Surveillance; VRE

Indexed keywords

AMPICILLIN; CEFTRIAXONE; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; OXACILLIN; PENICILLIN DERIVATIVE; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUSTRALIA; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; BROTH DILUTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG POTENCY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; EUROPE; GRAM POSITIVE BACTERIUM; INDIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NEW ZEALAND; NONHUMAN; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; AUSTRALASIA; DAPTOMYCIN; EUROPE; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LATIN AMERICA; MICROBIAL SENSITIVITY TESTS;

EID: 84875240521     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.01.001     Document Type: Article

References (37)

1. Abdel-Rahman S.M., Chandorkar G., Akins R.L., Bradley J.S., Jacobs R.F., Donovan J., et al. Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg/kg in children aged 2 to 6 years with suspected or proved Gram-positive infections. Pediatr Infect Dis J 2011, 30:712-714.
2. Avery L.M., Steed M.E., Woodruff A.E., Hasan M., Rybak M.J. Daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus vertebral ssteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 2012, 56:5990-5993.
3. Bell J.M., Turnidge J.D., Sader H.S., Jones R.N. Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008). Pathology 2010, 42:470-473.
4. Berti A.D., Wergin J.E., Girdaukas G.G., Hetzel S.J., Sakoulas G., Rose W.E. Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics. Antimicrob Agents Chemother 2012, 56:5046-5053.
5. Bertsche U., Weidenmaier C., Kuehner D., Yang S.J., Baur S., Wanner S., et al. Correlation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and d-alanylation. Antimicrob Agents Chemother 2011, 55:3922-3928.
6. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: ninth edition, M07-A9 2012, CLSI, Wayne, PA.
7. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing: 23rd informational supplement (M100-S23) 2013, CLSI, Wayne, PA.
8. Crank C.W., Scheetz M.H., Brielmaier B., Rose W.E., Patel G.P., Ritchie D.J., et al. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: a retrospective, multicenter, cohort study. Clin Ther 2010, 32:1713-1719.
9. Cubicin Package Insert, 2012. Cubist Pharmaceuticals, Inc, Lexington, MA. Available at . Accessed January 1, 2012. http://www.cubicin.com/pdf/PrescribingInformation.pdf.
10. D'Souza N., Shetty A., Mehta A., Rodrigues C. Antimicrobial susceptibility profiles of meticillin-susceptible and -resistant Staphylococcus aureus: focus on daptomycin minimum inhibitory concentrations at a tertiary care centre in Mumbai, India. Int J Antimicrob Agents 2010, 36:267-270.
11. Dhand A., Bayer A.S., Pogliano J., Yang S.J., Bolaris M., Nizet V., et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011, 53:158-163.
12. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 2.0, January 2012. Available at . Accessed January 1, 2012. http://www.eucast.org/clinical_breakpoints/.
13. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0, January 2013. Available at . Accessed October 1, 2012. http://www.eucast.org/clinical_breakpoints/.
14. Falcone M., Russo A., Pompeo M.E., Vena A., Marruncheddu L., Ciccaglioni A., et al. Retrospective case-control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy. Int J Antimicrob Agents 2012, 39:64-68.
15. Friedman L., Alder J.D., Silverman J.A. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 2006, 50:2137-2145.
16. Gonzalez-Ruiz A., Beiras-Fernandez A., Lehmkuhl H., Seaton R.A., Loeffler J., Chaves R.L. Clinical experience with daptomycin in Europe: The first 2.5 years. J Antimicrob Chemother 2011, 66:912-919.
17. Humphries R.M., Kelesidis T., Tewhey R., Rose W.E., Schork N., Nizet V., et al. Genotypic and phenotypic evaluation of the evolution of high-level daptomycin nonsusceptibility in vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2012, 56:6051-6053.
18. Kao T.M., Wang J.T., Weng C.M., Chen Y.C., Chang S.C. In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006-2008: stratified analysis by vancomycin MIC. J Microbiol Immunol Infect 2011, 44:346-351.
19. King E.A., McCoy D., Desai S., Nyirenda T., Bicking K. Vancomycin-resistant enterococcal bacteraemia and daptomycin: Are higher doses necessary?. J Antimicrob Chemother 2011, 66:2112-2118.
20. Lai C.C., Sheng W.H., Wang J.T., Liao C.H., Ho M.W., Chen C.J., et al. Safety and efficacy of daptomycin for the treatment of hospitalized adult patients in Taiwan with severe staphylococcal infections. J Microbiol Immunol Infect 2012, 45:52-57.
21. Mathai D., Biedenbach D.J., Jones R.N., Bell J.M., Turnidge J., Sader H.S. Activity of daptomycin against Gram-positive bacterial isolates from Indian medical centres (2006-2007). Int J Antimicrob Agents 2009, 34:497-499.
22. Mehta S., Singh C., Plata K.B., Chanda P.K., Paul A., Riosa S., et al. Beta-lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother 2012, 56:6192-6200.
23. Mendes R.E., Jones R.N., Deshpande L.M., Ross J.E., Sader H.S. Daptomycin activity tested against linezolid-nonsusceptible Gram-positive clinical isolates. Microb Drug Resist 2009, 15:245-249.
24. Mishra N.N., Bayer A.S., Moise P.A., Yeaman M.R., Sakoulas G. Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patients. J Infect Dis 2012, 206:1160-1167.
25. Moore C.L., Osaki-Kiyan P., Haque N.Z., Perri M.B., Donabedian S., Zervos M.J. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 2012, 54:51-58.
26. Rose W.E., Schulz L.T., Andes D., Striker R., Berti A.D., Hutson P.R., et al. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother 2012, 56:5296-5302.
27. Sader H.S., Becker H.K., Moet G.J., Jones R.N. Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 μg/mL isolated in the United States and European hospitals (2006-2008). Diagn Microbiol Infect Dis 2010, 66:329-331.
28. Sader H.S., Farrell D.J., Jones R.N. Antimicrobial activity of daptomycin tested against Gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009). J Chemother 2011, 23:200-206.
29. Sader H.S., Fey P.D., Fish D.N., Limaye A.P., Pankey G., Rahal J., et al. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother 2009, 53:4127-4132.
30. Sader H.S., Jones R.N. Antimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative Staphylococcus. Diagn Microbiol Infect Dis 2012, 73:212-214.
31. Sader H.S., Moet G.J., Farrell D.J., Jones R.N. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010). Diagn Microbiol Infect Dis 2011, 70:412-416.
32. Sakoulas G., Bayer A.S., Pogliano J., Tsuji B.T., Yang S.J., Mishra N.N., et al. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2012, 56:838-844.
33. Steed M.E., Werth B.J., Ireland C.E., Rybak M.J. Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Antimicrob Agents Chemother 2012, 56:5709-5714.
34. Tsai H.Y., Liao C.H., Chen Y.H., Lu P.L., Huang C.H., Lu C.T., et al. Trends in susceptibility of vancomycin-resistant Enterococcus faecium to tigecycline, daptomycin, and linezolid and molecular epidemiology of the isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006 to 2010. Antimicrob Agents Chemother 2012, 56:3402-3405.
35. Tygacil Package Insert, 2011. Wyeth Pharmaceuticals, Philadelphia, PA. Available at . Accessed September 2012. http://www.tygacil.com.
36. Werner G., Coque T.M., Hammerum A.M., Hope R., Hryniewicz W., Johnson A., et al. Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill 2008, 13:19046.
37. Weston A., Boucher H.W. Daptomycin for methicillin-resistant Staphylococcus aureus bloodstream infection and elevated vancomycin minimum inhibitory concentrations: Has the time come?. Clin Infect Dis 2012, 54:59-61.